Table 3.

Most Common Intralesional Therapies

Therapy	Number of Studies Using Therapy	Number of Patients across Studies1	Type of Warts (Number of Studies)	Dose Concentration and Amount	Dose Frequency and Number of Sessions2	Complete Response Rate3
MMR	24	807	vulgaris (13), palmaris (8), plantaris (13), periungual (7), plana (3), not specified (4)	20–100 IU/ml, 0.1–0.5 ml	Every 2, 3, or 4 wk, 2–8 sessions	27–90%
PPD	19	631	vulgaris (7), palmaris (5), plantaris (8), periungual (6), plana (2), not specified (3)	2.5–100 TU/ml, 0.1–0.3 ml	Every 1, 2, or 4 wk, 3–12 sessions	48–87%
Vitamin D3	15	423	vulgaris (7), palmaris (5), plantaris (11), periungual (4), plana (2), not specified (1)	2.5–15 mg/ml, 0.1–0.6 ml	Every 2, 3, or 4 wk, 2–8 sessions	40–96%
Candida	14	508	vulgaris (7), palmaris (2), plantaris (9), periungual (2), plana (3), not specified (0)	0.1–10 mg/ml, 0.1–0.3 ml	Every 2, 3, or 4 wk, 3–6 sessions	25–84%

Abbreviations: MMR, measles, mumps, rubella vaccine; PPD, purified protein derivative; RCT, randomized controlled trial.

All therapies are described in greater than 10 RCTs.

¹With complete follow-up (excludes those lost to follow-up).

²Sessions are reported as treatment until complete response or maximum number of sessions.

³Reported as a range from lowest to highest complete response rate.